Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function

Chemotherapy

Volumn 52, Issue 5, 2006, Pages 245-253

  Tajima, Naoyuki ^a   Ishizuka, Hitoshi ^a   Naganuma, Hideo ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Creatinine clearance; Dosage regimen; Panipenem betamipron; Population pharmacokinetics; Renal function

Indexed keywords

BETAMIPRON; PANIPENEM; PANIPENEM PLUS BETAMIPRON;

ADULT; AGED; ARTICLE; BACTERIOSTASIS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; HAEMOPHILUS INFLUENZAE; HUMANS; KIDNEY FAILURE; KIDNEY FUNCTION TESTS; METABOLIC CLEARANCE RATE; MIDDLE AGED; RENAL INSUFFICIENCY; THIENAMYCINS;

EID: 33747829623     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094745     Document Type: Article

References (26)

1. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA: Comparative pharmacokinetics of the carbapenems. Clin Pharmacokinet 2000;39:185-201.
2. Watanabe A, Tokue Y, Takahashi H, Kikuchi T, Kobayashi T, Gomi K, Fujimura S, Yasui S, Murayama Y, Nukiwa T: Comparative invitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001;7:267-271.
3. Gao KL, Noble S: Panipenem/betamipron. Drugs 2003;63:913-925.
4. Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y: Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrob Agents Chemother 1992;36:1810-1816.
5. Manabe S, Kimura K, Matsumoto E, Matsumoto E, Matsunuma N, Masuda H: Subacute toxicological study in rats treated intravenously with panipenem/betamipron for 90 days. Chemotherapy (Tokyo) 1991;39(suppl 3):157-165.
6. Hirouchi Y, Naganuma H, Kawahara Y, Okada R, Kamiya A, Inui K, Hori R: Preventive effect of betamipron on nephrotoxicity and uptake of carbapenems in rabbit renal cortex. Jpn J Pharmacol 1994;66:1-6.
7. Naganuma H, Tokiwa H, Hirouchi Y, Kawahara Y, Fukushige J, Fukami M, Hirota K, Muramatsu S, Takahagi H, Inui K, Tanigawara Y, Yasuhara M, Hori R, Kuwahara S: Nephroprotective effect and its mechanism of betamipron. 1. Relationships of renal transport. Chemotherapy (Tokyo) 1991;39(suppl 3):166-177.
8. Nakashima M, Uematsu T, Kanamaru M, Tajima M, Naganuma H, Hisaoka M, Kawahara Y, Takahagi H: Phase I study of panipenem/betamipron I: single dose study. Chemotherapy (Tokyo) 1991;39(suppl 3):242-264.
9. Nakashima M, Uematsu T, Kanamaru M, Tajima M, Naganuma H, Ichikawa M, Hisaoka M, Kawahara Y, Takahagi H: Phase I study of panipenem/betamipron II: multiple dose study. Chemotherapy (Tokyo) 1991;39(suppl 3):265-288.
10. Aoki N, Usuda Y, Koda Y, Takasawa T, Wakabayashi N, Hayashi S, Nitta I, Honma C, Watanabe K: Clinical pharmacology and efficacy of panipenem/betamipron. Chemotherapy (Tokyo) 1991;39(suppl 3):372-384.
11. Ohashi N, Uematsu T, Nagashima S, Kanamaru M, Tajima N, Togawa A, Hishida A: Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease. J Infect Chemother 2005;11:24-31.
12. Buckley MM, Brogden RN, Barradell LB, Goa KL: Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1992;44:408-444.
13. Kimura T, Kokubun H, Nowatari M, Matsuura N, Sunakawa K, Kubo H: Population pharmacokinetics of panipenem in neonates and retrospective evaluation of dosage. J Antimicrob Chemother 2001;47:51-59.
14. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K: Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004;48:1159-1167.
15. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
16. Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezoid. Infect Dis Clin North Am 2003;17:479-501.
17. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP: Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004;26:1187-1198.
18. Ambrose PG, Grasela DM: The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumonias. Diagn Microbiol Infect Dis 2000;38:151-157.
19. Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sorgel F: Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49:1881-1889.
20. Hisaoka M, Ichikawa M, Terao T: Microbiological assay method for the determination of panipenem concentrations in the body fluids. Chemotherapy (Tokyo) 1991;39(suppl 3):190-196.
21. Hisaoka M, Naganuma H, Yamazaki Y, Takahagi H, Kawahara Y: High-performance liquid chromatography (HPLC) for the determination of panipenem/betamipron concentrations in body fluids. Chemotherapy (Tokyo) 1991;39(suppl 3):197-205.
22. Beal SL, Sheiner LB: NONMEM user's guides. NONMEM Project Group; University of California at San Francisco, 1998.
23. Ette EI: Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997;37:486-495.
24. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
25. Shiba K, Saito A, Shimada J, Kaji M, Hori S, Yoshida M, Sakai O, Matsumoto F, Imai T, Ueda Y: Fundamental and clinical studies on panipenem/betamipron. Chemotherapy (Tokyo) 1991;39(suppl 3):362-371.
26. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing; twelfth informational supplement M100-S12. NCCLS, Villanova, 1990.